PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.66 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $53.59 million versus the consensus estimate of $70.9 million.

"We have been aggressively pursuing our vision to build a leading, fully integrated, multiplatform biotech company," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "The addition of gene therapy aligns with our goal of developing treatments for more patients with rare disorders and the in-licensing of Tegsedi™ and Waylivra™ leverages our commercial expertise. Over the last 20 years, our desire to bring new therapeutics to patients has been based on scientific innovation and we are continuing that mission."

GUIDANCE:

PTC Therapeutics sees FY2018 revenue of $260-280 million, versus the consensus of $276.02 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.